10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
US biopharma company Millendo Therapeutics yesterday announced that it is discontinuing the development of livoletide as a potential treatment for Prader-Willi syndrome (PWS), a rare genetic condition. 7 April 2020
Bristol, UK-based Imophoron plans to begin pre-clinical tests on multiple COVID-19 vaccine candidates, together with the University of Bristol's COVID-19 Emergency Research (UNCOVER) Group. 7 April 2020
UK drug major GlaxoSmithKline is the latest to announce a link-up with Vir Biotechnology in search of coronavirus solutions, sending the latter’s share price up by nearly 20% during Monday morning. 6 April 2020
French company Polyplus-transfection is about to launch a new reagent that has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing. 6 April 2020
Following a positive opinion from the European Medicines Agency’s advisory body the CHMP in late February, Japanese pharma giant Takeda today announced that the European Commission has extended the current marketing authorization of Alunbrig (brigatinib). 6 April 2020
Gilead Sciences has announced a four-year collaboration with Second Genome, to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds. 6 April 2020
Oxford, UK-based biotech Izana Bioscience today announced the initiation of a two-center compassionate use study involving namilumab (IZN-101) in the treatment of patients with rapidly worsening COVID-19 in cooperation with the Humanitas research group. 6 April 2020
Samsung Biologics has entered into a strategic partnership with PharmAbcine for the development and manufacturing of oncology and neovascular candidate PMC-402. 6 April 2020
The US Food and Drug Administration has approved Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent (EMA), for the treatment of anemia failing an erythropoiesis stimulating agent. 6 April 2020
As the destructive power of COVID-19 skulks through the bourses of every continent, the first quarter of 2020 has delivered a punishing blow for investors in stocks of every stripe. 3 April 2020
Shares in Fate Therapeutics are up more than a tenth after the cellular immunotherapy specialist unveiled a global collaboration and option agreement with Johnson & Johnson. 3 April 2020
UK-based clinical-stage biotech Axon Neuroscience presented positive results of its Phase II trial for AADvac1, the first tau vaccine to treat and prevent Alzheimer's disease, at the AAT-AD/PD (International Conference on Alzheimer’s & Parkinson’s Diseases) 2020 conference, Vienna, Austria. 3 April 2020
The pivotal Phase III clinical trial results announced today show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) in children aged six-11 years with uncontrolled severe atopic dermatitis significantly improved disease signs, symptoms and health-related quality of life. 3 April 2020
Closely-held US biotech firm Ridgeback Biotherapeutics yesterday announced that it has been awarded a contract for $10.9 million to support the development of ansuvimab (mAb114), an experimental Ebola treatment, through licensure with the US Food and Drug Administration. 3 April 2020
Privately-held drugmaker EUSA Pharma has announced initial preliminary findings from the SISCO study of siltuximab as a treatment for severe COVID-19. 2 April 2020
Austrian immuno-oncology firm Apeiron Biologics today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID-19. 2 April 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024